Point72 Hong Kong LTD Humanigen, Inc Transaction History

Point72 Hong Kong LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.76 - $3.33 $15,236 - $28,827	-8,657 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.81 - $3.97 $1,985 - $4,355	1,097 Added 14.51%	8,657 $26,000
Q4 2021 Feb 14, 2022	SELL	$3.66 - $8.22 $12,806 - $28,761	-3,499 Reduced 31.64%	7,560 $28,000
Q3 2021 Nov 15, 2021	BUY	$5.93 - $17.83 $65,200 - $196,040	10,995 Added 17179.69%	11,059 $66,000
Q2 2021 Aug 16, 2021	BUY	$13.54 - $22.74 $866 - $1,455	64 New	64 $1,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.